Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 12095987 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Hashimoto M, et al. (2002) Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection. J Biol Chem 277, 32985-91 12095987
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T308-p - Akt1 (mouse) ▲
Orthologous residues
Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  'neuron, cortical'-brain, HT-22 (neuron), HT-4 (neuron)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
aFGF increase
LY294002 aFGF inhibit treatment-induced increase
U0126 aFGF no effect upon treatment-induced increase
PD98059 aFGF no effect upon treatment-induced increase

T203-p - ERK1 (mouse) ▲
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  'neuron, cortical'-brain, HT-22 (neuron), HT-4 (neuron)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
aFGF increase
U0126 aFGF inhibit treatment-induced increase
PD98059 aFGF inhibit treatment-induced increase
LY294002 aFGF no effect upon treatment-induced increase

Y205-p - ERK1 (mouse) ▲
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  'neuron, cortical'-brain, HT-22 (neuron), HT-4 (neuron)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
aFGF increase
U0126 aFGF inhibit treatment-induced increase
PD98059 aFGF inhibit treatment-induced increase
LY294002 aFGF no effect upon treatment-induced increase

T183-p - ERK2 (mouse) ▲
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  'neuron, cortical'-brain, HT-22 (neuron), HT-4 (neuron)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
aFGF increase
U0126 aFGF inhibit treatment-induced increase
PD98059 aFGF inhibit treatment-induced increase
LY294002 aFGF no effect upon treatment-induced increase

Y185-p - ERK2 (mouse) ▲
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  'neuron, cortical'-brain, HT-22 (neuron), HT-4 (neuron)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  mouse, rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
aFGF increase
U0126 aFGF inhibit treatment-induced increase
PD98059 aFGF inhibit treatment-induced increase
LY294002 aFGF no effect upon treatment-induced increase

S9-p - GSK3B (mouse) ▲
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S3‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  'neuron, cortical'-brain, HT-22 (neuron), HT-4 (neuron)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  mouse, rat
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (mouse) pharmacological inhibitor of upstream enzyme, transfection of dominant-negative enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
aFGF increase
LY294002 aFGF inhibit treatment-induced increase
U0126 aFGF no effect upon treatment-induced increase
PD98059 aFGF no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, inhibited


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.